Evaluation of the use of biocompatible implants in surgery of the lungs

<b>Actuality:</b> The problem of prevention and treatment of violations of Aero - and hemostasis remains relevant in modern lung surgery. This is especially true for patients who have a high risk of developing these complications in the form of the presence of factors such as COPD, emphysema and other concomitant diseases of the respiratory system. <b>Material and Methods:</b> The study included 69 patients operated for the period from 2015 to June 2018. In the main group - 35 patients (2017-2018) after resection or damaging the pulmonary parenchyma while separation of adhesions to provide Aero - and hemostasis on top of the defect tissue of the lung was superimposed “Heprocel” implant. The comparison group included 34 patients (2015-2017), comparable by sex, age, pathology, type of surgery and other objective criteria of homogeneity of the comparative analysis. <b>Results:</b> The use of the biological implant “Heprocel” has reduced the need for additional single stitching lung tissue to ensure adequate Aero - and hemostasis from 38.2% to 11.4% and multiple strengthening seams from 29.4% to 5.7% (χ2= 7,706; Df=2; P=0.021). The introduction of the domestic biological implant into lung surgery allowed to reduce the period to achieve Aero-and hemostasis from 32.8±2.5 to 12.5±1.2 minutes (P&lt;0.001), the total duration of the operation from 135.6±6.1 to 107.2±4.7 minutes (P&lt;0.001), as well as to reduce the duration of pleural drainage from 3.38±0.31 to 2.09±0.06 (P&lt;0.001) and the entire period of hospitalization from 12.1±0.4 to 10.7±0.2 days (P&lt;0.01).

Hali tarjima qilinmagan